SetPoint Medical Presents Positive Data from its Clinical Study of...
ProofofConcept Data Presented at Digestive Disease Week in Washington D.C. SetPoint Medical a clinicalstage biomedical technology company developing bioelectronic therapy for chronic inflammatory...
View ArticleQueens Medical Associates Hosts 12th Annual National Cancer Survivors Day...
Daylong event is a tribute to current patients and survivorsNEW YORK PRWEB June 13 2018 Queens Medical Associates a preeminent blood disorders and cancer care facility hosted a daylong celebration for...
View ArticleFermion's new plant operational in Hanko nearly 100 of production is exported
Orion CorporationÂÂ Press release 14 June 2018 at 9.00 a.m. Fermion's new plant operational in Hanko nearly 100 of production is exported Fermion Oy which manufactures active pharmaceutical...
View ArticleAggressive Lymphoma Linked with JAK Inhibitor Use
Small molecular inhibitors of the Janus kinase JAK signaling pathway have been developed of the past several years to effectively treat a host of disorders such as rheumatoid arthritis Crohns disease...
View ArticleLegal Prescriptions Getting Caught In Dragnet As FDA Tries To Catch Opioids...
Americans who have been buying cheaper prescribed medications internationally for conditions like Crohns disease are now paying a price. In other pharmaceutical news generic drug legislation trade...
View ArticleLateOnset Crohn's Disease Resembles Ulcerative Colitis
Crohn's disease CD diagnosed at age 55 years or later resembles ulcerative colitis UC and should be considered a distinct subgroup of inflammatory bowel disease IBD researchers report. Reuters Health...
View ArticleStrong outlook at Epistem
AIMlisted Epistem which was spun out of Christie Hospital's Paterson Institue and floated in 2007 operates a contract research services division which tests drugs under development for treating cancer...
View ArticleEpistem to present data from their model of Crohn's disease colitis at the...
MANCHESTER UNITED KINGDOM MarketwireSeptember 20 2010 Epistem plc LSE EHP the UK biotechnology and contract research company will present preclinical results from its recently completed colitis study...
View ArticleSetPoint Medical Reports Positive Longterm Results from its Clinical Study of...
Results presented at Annual European Congress of Rheumatology highlight strong therapy adherence and significant reduction in rheumatoid arthritis symptoms after 24months of therapy SetPoint Medical a...
View ArticlePsoriasis Treatments to Become Cheaper as Biosimilars Compete in $5 Billion...
A new study by iData Research estimates that there are nearly 150000 new cases of psoriasis PsO every year in the United States affecting 2.2 of the population. Approximately 80 of those affected have...
View ArticleAbbVie and Eisai Announce the Launch of HUMIRA Pen an AutoInjector...
TOKYO Jun 11 2018 JCN Newswire AbbVie GK Eisai Co. Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co. Ltd.announced that the autoinjection delivery system for HUMIRA...
View ArticleEfficacy safety and immunogenicity of adalimumab biosimilar BI 695501
Adalimumab is the most commonly prescribed biological and is approved for rheumatoid arthritis as well as psoriasis psoriatic arthritis along with Crohns and ulcerative colitis. Its patent life...
View ArticleBoehringer Ingelheim bolsters biologics research and development with 230...
New Biologicals Development Center in Biberach Germany bundles biologics development increases capacity and expands clinical supply network Increased development capacities reflect research pipeline...
View ArticleGenentechs TECENTRIQ in Combination with Chemotherapy Helped People with...
IMpower133 is the first Phase III study with an immunotherapybased combination to show improvement in overall survival and progressionfree survival in the initial treatment of extensivestage small cell...
View ArticleImmune cells that create and sustain chronic inflammatory bowel disease...
University of Alabama at Birmingham In preclinical experiments Laurie Harrington and colleagues have discovered a subset of immune cells that create and sustain chronic inflammatory bowel disease....
View ArticleMucosal Improvement and Healing in Crohn Disease Is Not Limited to AntiTNF...
A substudy of ustekinumab efficacy trials documents improvement in endoscopic endpoints.
View ArticleAerpio grants Gossamer rights to IBD program
In a deal potentially worth up to $420mm Aerpio Pharmaceuticals Inc. licensed Gossamer Bio Inc. exclusive global rights to develop and commercialize AKB4924 and related compounds for inflammatory bowel...
View ArticlePhase III IMpassion130 Study Showed Genentechs TECENTRIQ Plus Abraxane...
First Phase III immunotherapy study to demonstrate a statistically significant progressionfree survival PFS improvement in intentiontotreat ITT and PDL1 positive firstline metastatic triple negative...
View ArticleRedHill Biopharma Announces Allowance of Two New RHB104 Patents Ahead of...
RedHill has received Notices of Allowance for two new patents covering RHB104 in the U.S. and Europe which are expected to be valid until at least 2029 once grantedÂTopline results from the first Phase...
View ArticlePredictImmune Appoints New CEO
Paul Kinnon appointed to drive the companys next phase of development commercialisation and expansion PredictImmune a developer of pioneering prognostic products for guiding treatment options and...
View Article